Logo image of OBIO

ORCHESTRA BIOMED HOLDINGS IN (OBIO) Stock Price, Quote, News and Overview

NASDAQ:OBIO - Nasdaq - US68572M1062 - Common Stock - Currency: USD

3.34  0 (0%)

After market: 3.34 0 (0%)

OBIO Quote, Performance and Key Statistics

ORCHESTRA BIOMED HOLDINGS IN

NASDAQ:OBIO (6/10/2025, 8:00:02 PM)

After market: 3.34 0 (0%)

3.34

0 (0%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High8.87
52 Week Low2.37
Market Cap127.96M
Shares38.31M
Float25.32M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO08-04 2020-08-04


OBIO short term performance overview.The bars show the price performance of OBIO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20

OBIO long term performance overview.The bars show the price performance of OBIO in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of OBIO is 3.34 USD. In the past month the price increased by 26.04%. In the past year, price decreased by -58.09%.

ORCHESTRA BIOMED HOLDINGS IN / OBIO Daily stock chart

OBIO Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 28.06 233.36B
ISRG INTUITIVE SURGICAL INC 69.32 189.82B
SYK STRYKER CORP 30.73 147.15B
BSX BOSTON SCIENTIFIC CORP 36.79 146.97B
MDT MEDTRONIC PLC 15.99 112.81B
BDX BECTON DICKINSON AND CO 12.38 49.98B
EW EDWARDS LIFESCIENCES CORP 29.15 44.46B
IDXX IDEXX LABORATORIES INC 46.13 42.62B
RMD RESMED INC 27.83 37.05B
GEHC GE HEALTHCARE TECHNOLOGY 16.07 33.85B
DXCM DEXCOM INC 51.41 33.26B
STE STERIS PLC 25.95 23.81B

About OBIO

Company Profile

OBIO logo image Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania and currently employs 70 full-time employees. The company went IPO on 2020-08-04. Its lead product candidate is BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension (HTN), the leading risk factor for death worldwide. The company is also developing the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The company is developing bioelectronic therapies based on patented CNT technology. BackBeat CNT, also known as Atrioventricular Interval Modulation (AVIM) therapy, is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.

Company Info

ORCHESTRA BIOMED HOLDINGS IN

150 Union Square Drive

New Hope PENNSYLVANIA US

Employees: 56

OBIO Company Website

OBIO Investor Relations

Phone: 16463439298

ORCHESTRA BIOMED HOLDINGS IN / OBIO FAQ

What is the stock price of ORCHESTRA BIOMED HOLDINGS IN today?

The current stock price of OBIO is 3.34 USD.


What is the ticker symbol for ORCHESTRA BIOMED HOLDINGS IN stock?

The exchange symbol of ORCHESTRA BIOMED HOLDINGS IN is OBIO and it is listed on the Nasdaq exchange.


On which exchange is OBIO stock listed?

OBIO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ORCHESTRA BIOMED HOLDINGS IN stock?

13 analysts have analysed OBIO and the average price target is 13.84 USD. This implies a price increase of 314.46% is expected in the next year compared to the current price of 3.34. Check the ORCHESTRA BIOMED HOLDINGS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ORCHESTRA BIOMED HOLDINGS IN worth?

ORCHESTRA BIOMED HOLDINGS IN (OBIO) has a market capitalization of 127.96M USD. This makes OBIO a Micro Cap stock.


How many employees does ORCHESTRA BIOMED HOLDINGS IN have?

ORCHESTRA BIOMED HOLDINGS IN (OBIO) currently has 56 employees.


What are the support and resistance levels for ORCHESTRA BIOMED HOLDINGS IN (OBIO) stock?

ORCHESTRA BIOMED HOLDINGS IN (OBIO) has a support level at 2.99 and a resistance level at 3.35. Check the full technical report for a detailed analysis of OBIO support and resistance levels.


Is ORCHESTRA BIOMED HOLDINGS IN (OBIO) expected to grow?

The Revenue of ORCHESTRA BIOMED HOLDINGS IN (OBIO) is expected to grow by 1.24% in the next year. Check the estimates tab for more information on the OBIO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ORCHESTRA BIOMED HOLDINGS IN (OBIO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ORCHESTRA BIOMED HOLDINGS IN (OBIO) stock pay dividends?

OBIO does not pay a dividend.


What is the Price/Earnings (PE) ratio of ORCHESTRA BIOMED HOLDINGS IN (OBIO)?

ORCHESTRA BIOMED HOLDINGS IN (OBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.77).


What is the Short Interest ratio of ORCHESTRA BIOMED HOLDINGS IN (OBIO) stock?

The outstanding short interest for ORCHESTRA BIOMED HOLDINGS IN (OBIO) is 4.71% of its float. Check the ownership tab for more information on the OBIO short interest.


OBIO Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to OBIO. When comparing the yearly performance of all stocks, OBIO is a bad performer in the overall market: 94.06% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

OBIO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to OBIO. OBIO may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

OBIO Financial Highlights

Over the last trailing twelve months OBIO reported a non-GAAP Earnings per Share(EPS) of -1.77. The EPS decreased by -19.59% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -112.3%
ROE -393.4%
Debt/Equity 0.85
Chartmill High Growth Momentum
EPS Q2Q%-28.95%
Sales Q2Q%40%
EPS 1Y (TTM)-19.59%
Revenue 1Y (TTM)29.88%

OBIO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to OBIO. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of -22.99% and a revenue growth 1.24% for OBIO


Ownership
Inst Owners43.2%
Ins Owners4.1%
Short Float %4.71%
Short Ratio2.61
Analysts
Analysts84.62
Price Target13.84 (314.37%)
EPS Next Y-22.99%
Revenue Next Year1.24%